GlycoMimetics, Inc. (GLYC)
Largest Insider Buys in Sector
GLYC Stock Price History Chart
GLYC Stock Performance
About GlycoMimetics, Inc.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect …
Insider Activity of GlycoMimetics, Inc.
Over the last 12 months, insiders at GlycoMimetics, Inc. have bought $83,159 and sold $488,749 worth of GlycoMimetics, Inc. stock.
On average, over the past 5 years, insiders at GlycoMimetics, Inc. have bought $2.75M and sold $3.43M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rock Edwin (Chief Medical Officer) — $78,825. Hahn Brian M. (SVP Finance, CFO) — $4,335.
The last purchase of 115,000 shares for transaction amount of $30,717 was made by Rock Edwin (Chief Medical Officer) on 2024‑06‑21.
List of Insider Buy and Sell Transactions, GlycoMimetics, Inc.
| 2024-08-08 | Sale | 10 percent owner | 260,873 0.4135% | $0.19 | $50,009 | -12.10% | ||
| 2024-08-07 | Sale | 10 percent owner | 61,488 0.0996% | $0.18 | $11,197 | -5.39% | ||
| 2024-08-06 | Sale | 10 percent owner | 55,732 0.0882% | $0.18 | $10,188 | -7.70% | ||
| 2024-08-05 | Sale | 10 percent owner | 164,523 0.2612% | $0.19 | $30,996 | -9.94% | ||
| 2024-08-02 | Sale | 10 percent owner | 286,200 0.4383% | $0.20 | $57,354 | -18.03% | ||
| 2024-08-01 | Sale | 10 percent owner | 63,564 0.0987% | $0.22 | $13,743 | -22.69% | ||
| 2024-07-30 | Sale | 10 percent owner | 756,835 1.1897% | $0.22 | $167,185 | -1.31% | ||
| 2024-07-29 | Sale | 10 percent owner | 363,949 0.5697% | $0.24 | $85,637 | -27.96% | ||
| 2024-07-26 | Sale | 10 percent owner | 258,335 0.4016% | $0.24 | $62,440 | -29.93% | ||
| 2024-06-21 | Chief Medical Officer | 115,000 0.1787% | $0.27 | $30,717 | -33.85% | |||
| 2024-06-20 | Chief Medical Officer | 190,000 0.2799% | $0.25 | $48,108 | -31.32% | |||
| 2024-06-18 | SVP Finance, CFO | 17,500 0.0252% | $0.25 | $4,335 | -28.43% | |||
| 2023-09-22 | Chief Medical Officer | 30,403 0.0463% | $1.38 | $41,956 | +6.38% | |||
| 2023-09-21 | Chief Medical Officer | 35,000 0.0544% | $1.38 | $48,300 | +8.70% | |||
| 2023-05-17 | Sale | SVP Finance, CFO | 3,700 0.0059% | $1.95 | $7,215 | -15.69% | ||
| 2023-05-10 | director | 30,000 0.0441% | $1.56 | $46,800 | -1.14% | |||
| 2023-05-08 | SVP & Chief Commercial Officer | 13,500 0.0237% | $1.57 | $21,195 | +18.24% | |||
| 2023-02-24 | 10 percent owner | 100,000 0.1667% | $1.70 | $170,000 | -5.33% | |||
| 2023-02-23 | 10 percent owner | 200,000 0.3399% | $1.75 | $350,760 | -6.14% | |||
| 2023-02-22 | 10 percent owner | 150,000 0.2504% | $1.79 | $268,995 | -9.83% |
Insider Historical Profitability
| Invus Public Equities, L.P. | 10 percent owner | 6317565 9.7971% | $0.36 | 8 | 9 | <0.0001% |
| Rock Edwin | Chief Medical Officer | 680403 1.0552% | $0.36 | 7 | 0 | <0.0001% |
| Hahn Brian M. | SVP Finance, CFO | 70643 0.1096% | $0.36 | 2 | 3 | +32.26% |
| BVF PARTNERS L P/IL | 10 percent owner | 4980812 7.7241% | $0.36 | 3 | 0 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 4702791 7.293% | $0.36 | 1 | 2 | <0.0001% |
Institutional Investor Ownership
| Bvf Inc Il | $28.63M | 14.81 | 9.54M | 0% | +$0 | 0.21 | |
| Artal Group S A | $25.77M | 13.32 | 8.59M | 0% | +$0 | 0.11 | |
| Nea Management Company Llc | $11.51M | 5.95 | 3.84M | -19.51% | -$2.79M | 0.05 | |
| Octagon Capital Advisors LP | $9M | 4.65 | 3M | 0% | +$0 | 0.05 | |
| The Vanguard Group | $8.29M | 4.29 | 2.76M | +14.04% | +$1.02M | <0.0001 |